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Thirty adult patients who received intravenous colistin (5.1  2.4 mg/kg/day) were reviewed to evaluate
dosing with respect to nephrotoxicity, which occurred in 10 (33%) patients within the first 5 days of treatment.
Excessive colistin dosing was frequent (47%), often (71%) resulted from the use of actual body weight in obese
patients, and was associated with higher rates of nephrotoxicity (80% versus 30%, P  0.019).
Despite over 50 years of clinical use, definitive recommen-
dations regarding the most efficacious and least toxic way to
dose colistin do not exist (13). Package insert dosing recom-
mendations are often used, but these are inconsistent among
the different available products and were derived using inac-
curate pharmacokinetic data (12, 14, 16–18). Colistin use was
abandoned in the 1970s due to nephrotoxicity concerns and the
introduction of safer alternatives; recent studies have demon-
strated lower-than-expected rates of renal impairment (4–7).
The purpose of this study was to critically evaluate colistin
dosing with respect to the development of nephrotoxicity at a
large community teaching hospital.
A retrospective cohort study of adult patients treated with
intravenous (i.v.) colistimethate sodium for injection (Paddock
Laboratories, Minneapolis, MN) for 48 h or longer from 2006
to 2008 at Orlando Health was conducted. Each vial contained
150 mg of colistin base activity (CBA). Throughout this paper,
the term colistin refers to colistimethate sodium for injection
and dosing is expressed as CBA. Patients were excluded if on
dialysis at the start of colistin treatment. The study was ap-
proved by both the Orlando Health and University of Florida
Institutional Review Boards.
The following clinical data were collected for each patient:
age, gender, comorbidities, Acute Physiology and Chronic
Health Evaluation (APACHE) II score (10), weight and hos-
pital ward at the time of colistin initiation, dose and duration
of all colistin administered, concomitant nephrotoxic agents,
and serum creatinine (SCR) levels.
Colistin dosing was evaluated based on two weight-based
daily milligram of colistin per kilogram of body weight regi-
mens: actual body weight (ABW) and ideal body weight
(IBW). Ideal body weight, in kilograms, was calculated as fol-
lows: 50  2.3  (height in inches exceeding 5 feet) for men;
45.5 2.3 (height in inches exceeding 5 feet) for women (2).
Patients were considered obese if the ABW was greater than
140% of the IBW. Classification of each dosing regimen was
based on a modification of the package insert as described by
Evans et al. (3), in which dosing recommendations are based
on creatinine clearance (CrCl) estimates (1). A daily dose was
considered excessive, normal, or low-normal if it was greater
than, within, or below 0.4 mg/kg/day, respectively, of the
recommended dosing range using IBW.
Nephrotoxicity was defined as at least two consecutive SCR
measurements with an increase of 0.5 mg/dl from baseline at
least 24 h apart after two or more days of colistin therapy. The
RIFLE criteria were used to evaluate the severity of acute
kidney injury (9).
All statistical analyses were performed using SPSS version
14.0 for Windows (Chicago, IL). Continuous variables were
analyzed using either the t test or the Mann-Whitney U test;
categorical data were compared using either the 2 or Fisher’s
exact test when appropriate.
Thirty patients were prescribed colistin for treatment of
multidrug-resistant Pseudomonas aeruginosa and Klebsiella
pneumoniae isolated primarily from respiratory (63%) or
urine (20%) sources. The mean cumulative intravenous colis-
tin dose was 2,559  2,088 mg and was administered for a
median of 8 (range, 3 to 24) days. Dosing of colistin based on
ABW and IBW was 3.9  1.2 and 5.1  2.4 mg/kg/day, respec-
tively. Subsequent analysis of dosing is listed in Table 1. Four-
teen patients (47%) received an excessive colistin dose. In 10
of these cases (71%), the dose was calculated based on ABW,
instead of IBW, in obese patients. Eleven patients (37%) re-
ceived low-normal doses (Table 1).
Ten patients (33%) developed nephrotoxicity during colistin
treatment; all had baseline SCR values 1.4 mg/dl, received
greater than 4 mg/kg/day, and developed renal impairment
within the first 5 days of treatment. The median SCR at the
beginning and end of therapy was 1.0 and 2.5 mg/dl, respectively.
Based on RIFLE criteria, 3, 5, and 2 patients met the criteria for
injury, failure, and end-stage kidney disease, respectively. Table 2
lists a comparison of patient characteristics based on develop-
ment of nephrotoxicity. Patients who developed nephrotoxicity
were older, had a higher baseline APACHE II score, and were
more likely to have been treated in an intensive care unit
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(ICU); however, only age was statistically significant. No dif-
ferences in treatment duration or cumulative dose of colistin
were observed; however, patients administered excessive daily
colistin doses were significantly more likely to develop neph-
rotoxicity than those who received normal or low-normal doses
(P  0.019). Patients who received excessive doses because
ABW was used for dose calculation in the obese were 13.2
times more likely to develop nephrotoxicity (95% confidence
interval, 2.1, 82.1) than patients who received normal or low-
normal doses (P  0.005). Alternative explanations for devel-
oping nephrotoxicity that were statistically significant included
receipt of concomitant diuretics and/or vasopressors. All four
patients receiving vasopressors in this study developed neph-
rotoxicity; the remaining six patients who developed nephro-
toxicity all received excessive daily colistin doses.
The major findings of this study were the 33% nephrotoxic-
ity rate among hospitalized patients who received colistin, the
statistically significant association between development of
nephrotoxicity and excessive colistin dosing, and the observa-
tion that excessive colistin doses were usually administered
because ABW rather than IBW was used to calculate the daily
mg/kg dose. For example, in one 166-kg patient with a CrCl
120 ml/min at baseline, a 5.1-mg/kg/day dose based on ABW
was given. Based on IBW, however, the dose given was 14.3
mg/kg/day. The patient developed nephrotoxicity on day 2 of
therapy. Although the IBW is recommended in the package
insert, data validating this recommendation do not exist and it
is unclear which weight measure is most appropriate. Alterna-
tive reasons other than colistin dosing that could have ex-
plained development of nephrotoxicity were older age, receipt
of diuretics, and receipt of vasopressors. After patients who
received vasopressors were excluded from the analysis, neph-
rotoxicity was observed only in patients who received excessive
daily dosing. Due to the small number of patients remaining
TABLE 1. Intravenous colistin dosing based on renal function
Dose description
Recommended dosingb based on baseline
creatinine clearance:
80 ml/min
(n  20)
30–80 ml/min
(n  10)
Recommended dosea 5 mg/kg/day 2.5–3.8 mg/kg/day
Dosing based on:
Actual body weight 4.2 1.2 3.3 1.1
Ideal body weight 5.3 2.9 4.7 1.2
Analysis of patient dosec:
Excessive 9.0 3.8 (n  5) 5.0  0.6 (n  9)
Normal 5.0 0.3 (n  5) None
Low-normalc 3.6  0.7 (n  10) 1.8 (n  1)
a Dosing recommendations based on those of Evans et al. (3).
b All dosing expressed as mean  standard deviation in mg/kg/day.
c Excessive, normal, or low-normal dosing corresponded to a daily dose that
was greater than, within, or lower than 0.4 mg/kg/day, respectively, of the rec-
ommended dose using ideal body weight. Creatinine clearance as calculated by
Cockcroft and Gault (1).
TABLE 2. Patient characteristics based on the development of nephrotoxicity during intravenous colistin therapy (n  30)
Characteristica
Result for patient type
P value
Nephrotoxic (n  10) Nonnephrotoxic(n  20)
Demographics
Age in years (mean  SD) 57.5  15.5 43.3  16.5 0.033
APACHE II score 13 (7–18) 7 (3–15) 0.122
Male (%) 60 65 1.000
ICU stay during colistin administration (%) 50 25 0.231
Colistin dosing
SCR at beginning, mg/dl 1.0 (0.6–1.2) 0.8 (0.5–0.9) 0.298
SCR at end, mg/dl 2.5 (2.1–4.0) 0.7 (0.5–0.9) 0.001
CrCl at beginning, ml/min 86 (60–144) 122 (77–144) 0.301
Treatment duration, days 7 (5–16) 9 (5–12) 0.947
Every-12-h dosing frequencyb (%) 90 65 0.210
Dose per ABW, mg/kg/day 4.2 (3.4–5.0) 4.0 (2.7–4.6) 0.301
Dose per IBW, mg/kg/day 5.5 (4.6–7.7) 4.4 (3.1–5.3) 0.011
Cumulative i.v. dose, mg 1,838 (1,519–4,613) 1,823 (975–3,184) 0.455
Cumulative i.v.  aerosolized dose, mg 1,838 (1,519–6,263) 1,823 (975–3,430) 0.455
Excessive daily dosing (all) (%) 80 30 0.019
Excessive daily dosing (because ABW used in obese patient) (%) 70 15 0.005
Alternative explanations for nephrotoxicityc
i.v. contrast use (%) 20 35 0.675
Concomitant vancomycin (%) 50 30 0.425
Concomitant aminoglycosides (%) 30 40 0.702
Concomitant ACE/ARBs (%) 40 15 0.181
Concomitant diuretic use (%) 80 20 0.004
Concomitant vasopressors (%) 40 0 0.008
a All data represent median results (25th to 75th percentile interquartile range [IQR]) unless otherwise stated. Abbreviations: APACHE, Acute Physiology and
Chronic Health Evaluation; ICU, intensive care unit; SCR, serum creatinine; CrCl, creatinine clearance as calculated by Cockcroft and Gault (1); ABW, actual body
weight; IBW, ideal body weight; ACE, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; SD, standard deviation.
b Every-8-h and every-6-h dosing frequencies were administered in six patients and one patient, respectively. No patients received an every-24-h dosing regimen.
c Nonsteroidal antiinflammatory drugs, cyclooxygenase-2 inhibitors, and amphotericin B were not given in this cohort.
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(n  26), a multivariate logistic regression model could not be
performed.
The 33% rate of nephrotoxicity observed is similar to a
report by Levin et al. (11) but higher than those found in other
contemporary studies (4–7, 15). The majority of these studies
used less than 3 mg/kg/day of CBA (4–7). The higher dosing of
5.5 mg/kg/day in patients who developed nephrotoxicity in this
cohort may account for the differences among studies. Wallace
et al. found a higher incidence of renal lesions in rats receiving
once-daily administration of a clinically relevant colistin dose
compared to a twice-daily regimen (19). Since all patients were
dosed multiple times daily in this cohort, this relationship
could not be evaluated. Additionally, a study by Hartzell et al.
(8) found that patients treated with colistin for greater than 14
days were 3.7 times more likely to develop nephrotoxicity.
Since all patients developed nephrotoxicity by day 5 of therapy,
this relationship could not be evaluated.
Contemporary, reliable colistin pharmacokinetic (PK) data
show a much lower concentration-time profile than previously
described (12, 14, 16, 18). For example, a report by Plachouras
et al. (18) shows sub-MIC colistin concentrations during the
first few days of therapy in critically ill patients. These PK data
suggest that increased daily doses are warranted; however, the
data from this analysis suggest that administration of any daily
colistin dose greater than that currently recommended (i.e., 2.5
to 5 mg/kg/day) be done cautiously, as this may increase neph-
rotoxicity risk.
In conclusion, excessive daily colistin dosing led to the more
frequent development of nephrotoxicity and was often due to
the use of the ABW for dose calculation in obese patients.
These data suggest that using a measure of lean body mass,
such as IBW, to dose colistin may be less nephrotoxic. Close
monitoring of renal function, specifically during the first 5 days
of therapy, may identify patients in whom renal toxicity of
colistin is likely to occur. Further investigation must continue
to identify the optimal colistin dose from both efficacy and
toxicity perspectives.
This work was not funded. All authors have no conflict of interest.
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